Arcus Biosciences

BioAge Labs halted azelaprag trials due to safety concerns; Biohaven's taldefgrobep alfa showed muscle-preserving effects in failed SMA trial, prompting obesity study. Roche's tiragolumab failed phase 3, dimming anti-TIGIT drug prospects; Gilead/Arcus' domvanalimab shows promise. AbbVie's emraclidine failed schizophrenia trials, impacting market cap. Cassava's simufilam failed Alzheimer's phase 3, amid SEC investigation.

DelveInsight's report on PD-1 Non-Small Cell Lung Cancer Market (2020-2034) highlights market growth, approvals, prevalence, therapies, and companies like Merck, Bristol-Myers Squibb, Genentech, and others. Key therapies include KEYTRUDA, OPDIVO, TECENTRIQ, and TIZVENI. Market drivers include premium-priced targeted agents and therapy expansion, while barriers include premium pricing of emerging therapies.

Adenosine antagonists market growth driven by R&D in neurodegenerative diseases, oncology, and cardiovascular disorders. Innovations in formulation and delivery systems enhance efficacy and safety, increasing adoption. Key companies include Arcus Biosciences, Corvus Pharmaceuticals, Portage Biotech, Palobiofarm, iTeos Therapeutics. Promising drugs like Etrumadenant, Ciforadenant, PORT-6, and Inupadenant are in various clinical trial phases.

Oncolytics Biotech Inc. announces key progress and upcoming studies for breast and pancreatic cancer treatments, preparing for FDA accelerated approval. The company's lead intravenously administered immunotherapy, pelareorep, shows promising efficacy in ongoing trials, with plans to initiate a clinical trial to support accelerated FDA approval in 2025.

Roche's Phase 3 trial SKYSCRAPER-01 showed tiragolumab did not improve survival in advanced lung cancer, failing to meet primary goals. Despite earlier promising data, final analysis indicated no sustained benefit. Roche will review tiragolumab's development, while other companies continue TIGIT drug research, hoping for breakthroughs.

FDA approved zolbetuximab-clzb (Vylov) plus chemotherapy for HER2-negative, CLDN18.2-positive gastric/GEJ adenocarcinoma, addressing unmet need in PD-L1–low/HER2-negative patients. Routine CLDN18.2 testing is crucial for targeted therapy in previously non-targetable populations.

The ADC market, driven by technological advancements and personalized medicine, is expected to reach ~USD 26 billion by 2030 with a CAGR of ~14%. North America leads due to high cancer incidence and strong biopharmaceutical sector. Key players include F. Hoffmann-La Roche Ltd, DAIICHI SANKYO COMPANY, LIMITED, and Pfizer Inc. The market is dynamic, influenced by regulatory frameworks and innovation in linker technologies and payloads.

AstraZeneca's Phase IIIb BATURA trial of Airsupra (albuterol/budesonide) met its primary endpoint, showing a significant decline in severe asthma exacerbation risk in patients with intermittent or mild persistent asthma. Airsupra's safety profile remained consistent, with no new concerns reported.

Recent Phase II data from iTeos and GSK's anti-TIGIT therapy belrestotug plus anti-PD-1 Jemperli shows promising response rates in NSCLC patients, despite high-profile failures in the TIGIT space. Despite setbacks, companies like Roche and Merck continue TIGIT studies, emphasizing trial design's impact on outcomes. Insights suggest anti-TIGIT therapy may benefit patients with high CD-155 expression, potentially as combination therapy. Recent positive results from iTeos/GSK and Gilead/Arcus indicate a possible turning tide in TIGIT therapeutics.

Arcus Biosciences and AstraZeneca collaborate on a clinical trial to evaluate the combination of Arcus's HIF-2a inhibitor casdatifan and AstraZeneca's PD-1/CTLA-4 bispecific antibody volrustomig in clear cell renal cell carcinoma patients. This is their second collaboration, following the 2020 PACIFIC-8 trial. Arcus also shares positive results from the Phase II EDGE-Gastric study, showing improved progression-free survival with domvanalimab plus zimberelimab and chemotherapy in upper GI cancers.